QIAGEN and CosmosID launch new plugin for metagenomics analysis
Nov 22 2016

QIAGEN and CosmosID launch new plugin for metagenomics analysis

Bioinformatics expansion strengthens QIAGEN’s Sample to Insight metagenomics solutions

Hilden, Germany, and Aarhus, Denmark, November 22, 2016 – QIAGEN and CosmosID, a leading genomic big data company, today announced the launch of a metagenomics analysis plugin for the QIAGEN Microbial Genomics Pro Suite and CLC Genomics Workbench. The launch of the CosmosID plugin expands QIAGEN’s industry leading platform for NGS bioinformatics and strengthens its role as a provider of Sample to Insight metagenomics solutions.

The CosmosID plugin offers support for shotgun metagenomics and microbiome profiling for application in the fields of infectious disease, food safety, animal health, agriculture, and environmental analysis.

The addition of the CosmosID plugin to the QIAGEN Microbial Genomics Pro Suite brings researchers a truly comprehensive package of metagenomics and microbiome profiling applications that we now have conveniently integrated into a single, user friendly and scalable software environment”, said Laura Furmanski, Senior Vice President of QIAGEN’s Bioinformatics business area. “When working with complex metagenomics samples, accurately identifying pathogens and identifying genes involved in virulence or antibiotic resistance is crucial. Achieving this requires a combination of precision algorithms and highly curated content in reference databases. With the CosmosID plugin, QIAGEN users gain access to both, algorithms and databases.”

“The CosmosID plugin enables researchers to profile microbial communities fast, accurately and with strain level resolution. Results of comparative analyses of datasets are visually accessible in heat maps and principal component analysis plots”, said Manoj Dadlani, CEO of CosmosID. ”They start with raw sequencing data, use CosmosID for microbial identification and comparison, and QIAGEN bioinformatics for functional analysis. It’s a complete workflow and a natural fit by which these tools can be integrated.”

Metagenomics is a field of great interest and focus for QIAGEN. The company has built strong leadership positions from sample through the analysis. The market for metagenomics and microbiome research is currently growing at over 20%. QIAGEN delivers a range of specialized solutions guiding microbiome researchers from sample to insight. With delivering integrated and user friendly bioinformatics QIAGEN is addressing one of the major bottlenecks in the metagenomics workflow.  To learn more about QIAGEN’s offering in microbiome research, visit https://www.qiagenbioinformatics.com/solutions/microbial-genomics-solution/.



QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of June 30, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). 


Share this page